HopeStage
Back to all studies
TerminatedNCT03351244

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Medication studyAges 18–55Multiple countries
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 55 years.

Listed locations
Phoenix and 58 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: December 7, 2017
Recruitment status
Terminated
Enrollment listed in the registry
264
Sponsor
Boehringer Ingelheim
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, France, Canada, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT03351244
Official title
Show the full official title

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients With Schizophrenia.

Recruitment & locations

Terminated

Phoenix, United States · Costa Mesa, United States · Garden Grove, United States

52 more locations
  • Glendale, United States
  • Lemon Grove, United States
  • Los Angeles, United States
  • Oceanside, United States
  • Orange, United States
  • Torrance, United States
  • Hallandale, United States
  • Hialeah, United States
  • Maitland, United States
  • North Miami, United States
  • Orlando, United States
  • Atlanta, United States
  • Chicago, United States
  • Lake Charles, United States
  • Monroe, United States
  • Ann Arbor, United States
  • Flowood, United States
  • Saint Charles, United States
  • St Louis, United States
  • Las Vegas, United States
  • Berlin, United States
  • Cedarhurst, United States
  • New York, United States
  • Austin, United States
  • Irving, United States
  • Richardson, United States
  • Richmond, United States
  • Calgary, Canada
  • Penticton, Canada
  • Vancouver, Canada
  • Chatham, Canada
  • Toronto, Canada
  • Montreal, Canada
  • Montpellier, France
  • Paris, France
  • Rennes, France
  • Saint-Priest-en-Jarez, France
  • Toulon, France
  • Aichi, Toyoake, Japan
  • Chiba, Ichikawa, Japan
  • Fukuoka, Fukuoka, Japan
  • Kanagawa, Atsugi, Japan
  • Kanagawa, Kawasaki, Japan
  • Nara, Kashihara, Japan
  • Saga, Kanzaki-gun, Japan
  • Tokyo, Kodaira, Japan
  • Gwangju, South Korea
  • Seongnam, South Korea
  • Seoul, South Korea
  • Santander, Spain
  • Tainan, Taiwan
  • Taoyuan, Taiwan

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Does this study involve medication?

Yes. The study involves medication, including BI 409306 and Placebo.

Who can participate?

Listed age limits: 18 years to 55 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies